Biosimilars - Publications - Faculty & Research

June 9, 2023
Article

A Radical Treatment for Insulin Pricing

In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a... View Details

Keywords: Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States

Citation

Find at Harvard

Register to Read

June 2017
Teaching Note

QuintilesIMS: Biosimilar Marketing in England

By: John A. Quelch and Emily C. Boudreau

Teaching Note for HBS No. 517-054. View Details

Citation

Purchase

November 2016
Case

QuintilesIMS: Biosimilar Marketing in England

By: John A. Quelch and Emily C. Boudreau

QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details

Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England

Citation

Educators

Purchase

February 2016 (Revised February 2017)
Case

Alvogen

By: Daniel Isenberg and William Kerr

Alvogen is a young Icelandic generic pharmaceutical company, whose CEO believes that his global strategy will give them an edge in this competitive industry.
Robert Wessman, Alvogen’s CEO, was also previously the CEO of Actavis, another Icelandic generics... View Details

Keywords: Pharmaceutical Companies; Generic Drugs; Entrepreneurship; Globalization; Risk and Uncertainty; Pharmaceutical Industry; Iceland

Citation

Educators

Purchase